Sandra Swain
Hematology & Oncology · Bethesda, MDNPI 1386670032
Payments from drug & device makers
What this record shows
This record is dominated by other: $806,742 of the $1,031,234 with a category attached, or 78.2%. Pfizer accounts for 78.3% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $846,990 and has fallen 96.0% since, to $33,499 in 2025. Among hematology & oncology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 127 payments — averaging $8119.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$807K
- Napo Pharmaceuticals Inc$49K
- Roche Products Limited$36K
- F. Hoffmann-la Roche AG$26K
- Astrazeneca UK Limited$20K
- Daiichi Sankyo Inc.$18K
- plus $75K from 12 others
Across 23 payments — averaging $1081.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$18K
- Genentech, Inc.$6K
- Astrazeneca UK Limited$278
What the payments were for
- Consulting fees$150,47715%
- Speaking & faculty fees$11,4071%
- Travel & lodging$58,7626%
- Food & beverage$3,8350%
- Education$120%
- Other$806,74278%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 5 | $807,025 |
| Napo Pharmaceuticals Inc | 23 | $49,136 |
| Roche Products Limited | 23 | $35,883 |
| F. Hoffmann-la Roche AG | 17 | $25,758 |
| Astrazeneca UK Limited | 9 | $19,861 |
| Daiichi Sankyo Inc. | 11 | $18,209 |
| Chugai Pharmaceutical Co., Ltd. | 4 | $17,611 |
| Eli Lilly | 1 | $17,500 |
| Tersera Therapeutics LLC | 12 | $15,463 |
| Merck | 3 | $7,235 |
| AstraZeneca | 5 | $6,913 |
| Sanofi | 4 | $3,075 |
| Athenex Pharmaceutical Division, LLC | 4 | $3,000 |
| Genentech USA, Inc. | 2 | $2,403 |
| Genentech, Inc. | 1 | $1,815 |
| Caris MPI, Inc. | 1 | $233 |
| Genmab U.S., Inc. | 1 | $104 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mytesi$48,847
- Perjeta$24,934
- TECENTRIQ$19,055
- Enhertu$15,620
- ZOLADEX$15,281
- Herceptin$9,855
- Kadcyla$4,820
- Oral Paclitaxel$3,000
- Encequidar$3,000
- Itovebi$2,280
- LYNPARZA$566
- MI CANCER SEEK$233
- TIVDAK$104
How this compares
$1,031,234 in reported general payments places this provider in the 95th percentile of 242 hematology & oncology providers in Maryland.
Other hematology & oncology in Bethesda
- Ralph BocciaBethesda$3.1M
- Chitra RajagopalBethesda$89K
- Susan LeitmanBethesda$44K
- Giuseppe GiacconeBethesda$32K
- Phillip ScheinbergBethesda$27K
- Steven PavleticBethesda$13K
- Kashif AliSilver Spring$987K
- Ani BalmanoukianBaltimore$842K
- Benjamin LevyBaltimore$578K
- Patrick FordeBaltimore$269K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.